CLINICAL_TRIALS
trial_result
· 2019-03-01
Clinical Trial Update: Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib [Phase 3]
Summary
Phase 3 study evaluating cabozantinib vs placebo in hepatocellular carcinoma after sorafenib; completed with results posted in 2019.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Exelixis | Conditions: Hepatocellular Carcinoma | Phase 3 | Status: COMPLETED | Results posted: 2019-03-01